15^th Asia-Pacific Pharma Congress July 18-20, 2018 Melbourne, Australia

Biography:

Martha Rowe, Speech Pathologist since 2000 has spent years researching and developing papaya enzyme formulation as a result of her own difficulties with a dry mouth following surgery due to facial trauma in 2008.  She has worked in both Public and Private hospitals across Victoria and has been involved in clinical studies and patients management in the areas of dysphagia and dry mouth.

Abstract:

A dry mouth syndrome occurs when there is not enough saliva (spit) in the mouth. A dry mouth is a symptom of an underlying problem, rather than a disease in itself. Causes may include drugs or medication, dehydration, mouth breathing, Sjogren's syndrome, infection, nerve problems and some cancer treatments.  Our research aims were Investigate effects of papaya enzymes in patients with dry mouth, Create a product that super cedes current products on the market, Determine microbiological and immunological outcomes and Investigate Quality of Life Measures.  Our results found categorically that papya enzymes assist with maintaining a clean and moistened mouth, free of bacteria and assisted with the increase in saliva flow. 

Biography:

Venkateshwarlu K  has completed  his PhD  from Kakatiya University, Warangal, India and  he is working as Professor and Head, Department of Pharmaceutical Analysis, Vaagdevi college of  Pharmacy.  He has published more than 20 papers in reputed various associations like APTI etc.

Abstract:

The combination of Metformin and Glimepiride is widely used to treat type 2 diabetes. The present study was carried out to study the pharmacokinetic interactions between these two drugs used in combination. An available RP-HPLC method for simultaneous estimation of Metformin and Glimepiride was revalidated for future use. Albino rats of either sex were randomly distributed into four groups of six animals in each; they are housed in well ventilated Aluminium cages and maintained on uniform diet and temperature with 12hr light and dark cycle. In this study, the blood was collected from orbital sinuses using heparinised capillaries into a micro centrifugation tubes contain anti coagulant at 0, 1, 2, 4, 6, 8, 12 hrs after treatment. Plasma was separated by centrifugation and stored at -20ºC until further analysis. These samples are used to analyze for pharmacokinetic and pharmacodynamic toxicological i.e. SGOT-SGPT, Complete Blood Picture (CBP) and serum Creatinine Clearance. Metformin and Glimepiride levels were estimated by a sensitive RP-HPLC method. This study proves, single and multiple doses Metformin increases plasma concentrations of Glimepiride. There is significant increase in the AUC and decrease in clearance. In single dose studies this change could be because of the transient induction in CYP2C9. When Glimepiride is given in repeated doses (15 days) there could be induction of the microsomal liver CYP2C9 subsequently increasing the metabolism, decreasing clearance of Metformin & increasing the overall AUC. This combination has clearly shown the beneficial effect on the CBP  i.e. significant improvement in blood cell count, lymphocytes and neutrophills in particular.

Biography:

Angela Drew is a Product Ideation Consultant at Camargo Pharmaceutical Services. Angela has an academic background in inflammatory diseases and cancer, and a regulatory background in FDA submissions for approval via the 505(b)(2) regulatory pathway. Angela has industry experience with US and Australian regulatory submissions, and experience with global clinical program oversight. She is experienced in Product Ideation and design of drug development programs.

Abstract:

Background: There are 3 major pathways through which drugs can be approved in the US, depending on their similarity to existing drugs, and the source of data that will support the application (see image). The 505(b)(2) regulatory pathway relies to some extent on existing data that comes from sources other than Sponsor studies, and results in smaller development programs than that of previously unknown drugs. A 505(b)(2) approval usually relies heavily on well-designed bioavailability/ bioequivalence studies to bridge to the existing data.

Methodology & Theoretical Orientation: This talk will cover the basics of the US regulatory pathways, with special emphasis on products intended for approval via the 505(b)(2) pathway. Which products are appropriate for this pathway, typical features of 505(b)(2) development programs, and when a biowaiver is appropriate will be discussed. Further, a review of products that gained approval based on studies reported in the literature is provided.

Conclusions & Significance: The 505(b)(2) regulatory pathway allows a Sponsor to rely on existing data and therefore reduce the size or scope of the development program. BA/BE studies are often the tenet of a 505(b)(2) approval, and have distinct goals compared with pharmacokinetic studies conducted for 505(b)(1) or generic products. It is therefore critical that BA/BE studies be designed with the nuances of the 505(b)(2) pathway in mind, and to collect additional data that will further reduce the number of studies required for approval. When BA/BE studies are well designed and conducted, and with FDA feedback and input at the appropriate times, a Sponsor can expect reduced cost and time to market. 

Biography:

Ashraf Abadi has completed his PhD from the College of Pharmacy, University of Florida, USA and Cairo University. He is the head of Pharmaceutical Chemsitry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo and former Dean of the Faculty. He has published more than 80 papers in reputed journals and 7 patents and has been serving as an editorial board member and reviewer of reputed international pharmaceutical sciences journals. He supervised more than 6- Master and Ph.D. theses in the field of Drug Discovery and Pharmaceutical Chemistry.

Abstract:

NS5A is a dimeric protein and an interesting target to inhibit the replication of HCV. Reported here are two series of symmetric molecules with the scaffolds of 4, 4'-(buta-1,3-diyne- 1,4-diyl) dianiline core- and  3, 3'-(buta-1,3-diyne- 1,4-diyl) dianiline core, connected to a L/D-proline moiety, and capped with the methyl, ethyl, butyl, isobutyl and benzyl carbamate of L/D-valine, L/D-leucine and L-isoleucine amino acids. The compounds showed inhibitory effect on the replication of HCV genotype 1b in vitro with EC50s in the low picomolar range and SI50s of several orders of magnitude, Also some of the compounds showed pan-genotypic activitiy. Higher activities were associated with compounds showing curving of the core scaffolds that leads to better fit and interaction with the desired target.

Biography:

C.S. Kandasamy has completed his PhD at the age of 42 years from SunRise University and postgraduate studies from the TamilNadu Dr. M.G.R. Medical University, Chennai. He is the Professor & Vice Principal of RVS College of Pharmaceutical Sciences, a premier Pharmaceutical educational service organization. He has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute.

Abstract:

Background: Diseases are destroyers of health, well being, and life.  So, Arogya is the main constituent for excelling in life. Jaundice is one disease which has manifested itself as a curse for many years. Even today, there is no good allopathic medicine for treatment and complete cure of jaundice. This study aims to make a formulation for the cure of jaundice by combining various herbals to cure jaundice.

Methods: Based on the ethnomedical literature reviews, the crude drugs such as cardamom, ajowan, cinnamon, coriander, cumin, clove, ginger, and nutmeg were collected and subjected to various pharmacognostical, phytochemical, and analytical studies to assess its quality. After confirming the quality, the hepatoprotective polyherbal formulation (HEP-PRO) was formulated and their efficacy was analysed using various analytical and pharmacological studies. To assess the safety of HEP-PRO, clinical trials were conducted using this formulation at Ayushkaram Ayurveda Hospital, Coimbatore after obtaining Human Ethical Clearance approval by IEC, Institute of Applied Dermatology, Kasaragod.

Results: The present study has been carried out in 30 patients. All the patients were given HEP-PRO at a dose of 60 ml three times a day one hour after food. HEP-PRO provided significant relief in pyrexia by 36% (P<0.015), fatigue and yellow discoloration of sclera by 27 & 39% respectively (P<0.025), and yellow discoloration of urine by 32% (P<0.010). This also has reduced the yellow discoloration of nail and yellow discoloration of skin by 60% with a P value of 0.001, which is also statistically significant.

Conclusion: HEP-PRO has proved its efficacy in the management of jaundice.

Biography:

Ahmed M A Masaad is concerned with discovery of new drugs and he have innovations in many new drugs and drug delivery systems. He have memberships of many scientific society and editor of PSC journal. He published more than twenty scientific researches in many sides of pharmacy, he have discovered new treatment of cancer of colon and skin. He possess innovative certificates in drugs delivery system and new drugs which published in scientific  journal.

Abstract:

Hemorrhoids, also called piles, are vascular structures in the anal canal. In their normal state, they are cushions that help with stool control. They become a disease when swollen or inflamed; the unqualifiedly term "hemorrhoid" is often used to refer to the disease. The signs and symptoms of hemorrhoids depend on the type present. Internal hemorrhoids are usually present with painless, bright red rectal bleeding when defecating. External hemorrhoids often result in pain and swelling in the area of the anus. If bleeding occurs it is usually darker. The new treatment is mainly depend on mechanism of contract the connective tissue surrounding the venous around anus by effervescent tannin base with strong anti-bacterial, antifungal and anti-viral effect of formula. The safety of drugs was tested in rabbits, rats first and then the experiment was done in hundreds of patient under license of ethics committee of Taif University. The percentage of cure conducted was 99%, this success leads to relive of pain over millions of patients around the world and minimize the risk of surgery treatment and cost beside quick relive of disease in two to three weeks with no chance of relapse of disease again.

Biography:

Prakash Kinthada is a Professor in Chemistry at Sri Vidyanikethan Engineering college, JNTU University in Ananthapur, A. Rangam Peta, Tirupathi, India.

Abstract:

Cancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health. Cancer patients have burdened by drug induced toxic side effects, and no turned to seek help from the complementary and alternative medicine hoping for a better cure. Research on Platinum based drugs and Non Platinum based drugs is a Multi-Million Dollar Industry in USA and there is every need to produce safe drugs for the cure of this monstrous disease. Flavonoids have a long history of use in traditional medicines in many cultures. The phytochemical, curcumin is one of the major dietary flavonoid, belonging to a group of flavonol, Curcumin is a natural polyphenol. It is highly potential molecule capable of preventing and treating various cancers.  Various dietary chemo preventive agents, turmeric powder or its extract are broadly used as therapeutic preparations in Indian System of medicine. We provide a summarized synthesis and structural determination of Curcumin Oxime, Curcumin Thiosemicarbazone derivative of Gold (III) complex. The use of these analogs for prevention of cancer tumor progression and treatments of human malignancies. A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Au (III) complex and other complexes of Platinum, Palladium, Ruthenium, Copper etc.

My talk would mainly encompass different Transition Metal Complexes/Organometallic Compounds   that are presently used as drugs, especially Anticancer and Anti-HIV drugs, apart from Anti-inflammatory, Antimicrobial, Antibacterial and diseases like Arthritis and Parkinson’s Disease etc. The talk would mainly focus on the use of Medicinal Chemistry and it’s application to Drug Design and Development in Pharmaceutical Industry ,  especially    Transition Metal Complexes and Organometallic Compounds viz. Gold, Platinum, Palladium And Ruthenium apart from Copper, Cobalt, Iron,  Nickel, Zinc, Cadmium etc.

The main emphasis of my talk would be on Different class of Ligands, their Schiff’s Bases and Transition Metal Complexes especially Au, Pt, Pd and Ru, with the main aim of designing, developing very novel small molecules, as possible and extremely potential candidates as Anti-cancer and Anti-HIV drugs. The talk would provide an overview of current programs being undertaken in our laboratories, especially focused on the development of potent ligands capable of recognizing Binding sites and diverse strategies employed by my group for elucidation of Anti-Cancer and Anti-HIV drug Leads to Circumvent the problem caused by Cis-Platin.

We have synthesized and characterized several phytochemicals from Traditional Medicinal Plants and isolated some phytochemicals and  made the corresponding Oximes, Thiosemicarbazones and Substituted thiosemicarbazones as ligands and synthesized, characterized, structurally elucidated their Transition Metal Complexes especially with Gold, Platinum, Palladium, Ruthenium, Copper etc. and Studied their Anticancer Activity, Nuclease activity etc. and tested their potential as Anticancer Drugs.

The main aim of our extensive/preclinical Pharmaceutical development program is to investigate the use of these extremely novel small molecules-metal complexes/compounds of phytochemicals, flavanoids etc., which have very interesting structural features and properties and hence are excellent candidates as Anti-Cancer and Anti-HIV drugs .The main aim of our research is Design ,Development and Synthesis of Transition Metal Complexes/ Organometallic Compounds that would certainly help to bring this force of nature from BENCH to BEDSIDE and enhance Cancer Killing with less toxic effects and would certainly lead to initiation of clinical trials.

Biography:

Ezharul H Chowdhury is currently holding an Associate Professor position and a cluster leader of 'Biomedical Engineering' under Advanced Engineering Platform (AEP) at MONASH University (Sunway Campus). Prior to this appointment, he was a Senior Lecturer at International Medical University (IMU) since September 2008 and an independent Assistant Professor of Tokyo Institute of Technology (Tokyo Tech) as well as a Visiting Professor at Shizuoka Cancer Center Institute since 2006. He was awarded with 'Doctor of Engineering' in 2003 by Tokyo Tech where he also carried out a post-doctoral study and subsequently, served as a team leader. He has pioneered the development of a range of pH-sensitive inorganic nanoparticles as smart tools for efficient and targeted intracellular delivery of genetic materials, gene-silencing elements, proteins and classical anti-cancer drugs. He is currently applying this smart nanotechnology for the treatment of cancer, particularly breast carcinoma and cardiovascular diseases, such as diabetes. His team is now conducting pre-clinical trials with some interesting nano-formulations of classical anti-cancer drugs, therapeutic gene(s) and anti-sense RNAs (siRNAs). His research team is thus one of the leading groups in the world, having original and unique contributions in this multidisciplinary field. Currently he is supervising 8 PhD students and 1 Master student. His research projects have so far been funded internally through institutional grants as well as externally by the Japanese Government's Ministry of Education, Culture, Sports, Science & Technology (MEXT), Japan Society for the Promotion of Science (JSPS), the Malaysian Ministry of Science, Technology and Innovation (MOSTI) and Ministry of Higher Education (MOHE). He works as editorial board members for 5 international journals. His outstanding contributions have so far produced over 70 publications in the international journals of high repute and 5 Japanese and US patents.

Abstract:

Regardless of the administration routes, delivery of small molecule drugs to their target sites of action historically poses one of the biggest challenges due to their homogeneous tissue distribution, renal clearance and lack of target specificity. Nanotherapeutics have evolved as novel drug formulations at dimensions of roughly 1–100 nanometers by virtue of the integration of nanotechnology with medicine for treating and preventing critical human diseases effectively and precisely. The favorable pharmacokinetics with prolonged circulation time, selective endothelial permeability at several target tissues and high specificity for biological targets are the attractive attributes of nanopharmaceuticals driving the pharmaceutical industries to conduct a large number of pre- clinical and clinical trials, with enormous successes seen in the past in getting approval and commercialization of nanotechnology-based medical products. Diversified approaches based on synthetic, recombinant, hybridoma and phage display technologies have been undertaken to fabricate a variety of nanoparticulate and macromolecular carriers and drugs in order to overcome the multi-step extracellular and intracellular barriers and to facilitate development of novel strategies for therapeutic delivery and imaging.

Biography:

Dawit Simegnew has completed his BPharm at the age of 24 years from University of Gondar. Currently, he is working as Clinical pharmacist at Shambu General Hospital. He has 4 published original research articles in peer-reviewed journals. He was also awarded by Ethiopian pharmaceutical association in 2014/15 for his outstanding academic achievements in pharmacy.

Abstract:

The sale of antibiotics without medical prescription has been observed in many countries. The practice is more pronounced in developing and low income countries where legislations and regulations are weak. In these countries, antibiotics are illegally purchased without medical prescriptions and very little effort has been made to tackle the situation. The role of pharmacists in contributing to healthcare remains debatable. In Ethiopia, there are deficiencies in the quality of current professional practice. Community pharmacists are now seen as retailers and businessmen rather than health care providers. Ethiopians are therefore left to accept the helpful and harmful practices such pharmacists. Self-medication with antibiotics is a universal problem and variations regarding such practices are obvious around the globe. The practice cuts across culture, gender, age, health status, social status, race and occupation. Irrational use of antibiotics increases the risk of bacterial resistance and adverse drug reactions. It has been found to produce various adverse effects in humans. It is the objective of this paper to discuss the irrational use and non-prescription sale of antibiotics in Ethiopia. It will discuss the evidence, the concept of self-medication, resistance and interactions, legislation, probable solutions, changes
in practice and the concept of sustainability which would help guarantee the appropriate sale and rational use of antibiotics in Ethiopia.

Biography:

Muluye Melak Zenebe has completed his MSc at the age of 25 years from University of Gondar and now he is a PhD candidate at Taiwan international graduate program (TIGP), Taipei, Taiwan. He has published two papers in reputed journals.

Abstract:

Vernonia amygdalina (VA) is a tropical African plant of the Asteraceae family and is occasionally cultivated for its medicinal uses, which include as a treatment for diarrhea, skin wounds, fever mastitis and warms infection. The aim of this study is to isolate and elucidate the structure of some of the chemical constituents from the leaf of Vernonia amygdalina and its bioactivities. Methanol extract of Vernonia amygdalina, after repeated chromatography led to the isolation of a different compound, one of this compound (MM-4) is partially characterized based on the spectral data (IR, ¹H NMR, ¹³C NMR, and DEPT) and Extracts from Vernonia amygdalina have been shown to have antimicrobial activity.

Biography:

Zaka Un Nisa is working as a Faculty of Medicine in Quaid-i-Azam University in Islamabad, Pakistan.

Abstract:

Health care waste disposal is an alarming issue in these days. Improper disposal of injections and sharp wastes at open places exposes people to the risk of transmission of infectious diseases. Inappropriate methods of managing, treatment and disposal of health care waste can lead to an adverse effect on public health. This study highlights the unsafe disposal of injection and sharp waste in Rawalpindi, Pakistan. This study is conducted to explore the injection and sharp waste disposal practices at the community level clinics. In-depth scientific analysis study including the interviews of sanitary workers working in different community clinics is conducted. 65% claimed that they disposed of waste (syringes, swabs, dressings, needles) which they collected from clinics at open places and 35% stated that they dispose of waste in municipal bins. None of them has ever got training regarding injections and sharp waste disposal. Only 25% sanitary workers were aware of the hazardous effect of unsafe disposal of injection and sharp waste. 75% stated that they get injured one or more time while disposing of syringes. The reasons they stated of having injury were lack of time, lack of awareness regarding the transmission of infectious disease. There is an urgent need to develop safe and sustainable waste disposal method that is feasible at the clinic level. It is found that injections and sharp wastes from clinics are handled and disposed of together with domestic waste.  It is also concluded that the duty of health care waste disposal is delegated to illiterate people who perform their duties without adequate knowledge and protective measures. Therefore, it is recommended that government and local health authorties should give immediate attention to this issue and setup a proper sustainable clinic waste disposal system.